MyFinsight
Home
Blog
About
Proceeds received from
sale of assets
$1,770K
Proceeds from issuance of
shares under employee...
$280K
Net cash used in
investing activities
$1,757K
(1355.00%↑ Y/Y)
Net cash (used in)
provided by financing...
$136K
(-99.91%↓ Y/Y)
Canceled cashflow
$13K
Canceled cashflow
$144K
Net (decrease)
increase in cash, cash...
-$17,570K
(-114.89%↓ Y/Y)
Canceled cashflow
$1,893K
Share-based compensation
expense
$3,965K
(-39.64%↓ Y/Y)
Accrued expenses and
other current...
$2,974K
Accounts
payable-Nonrelated Party
$1,496K
(447.10%↑ Y/Y)
Non-cash lease expense
$101K
(339.13%↑ Y/Y)
Depreciation expense
$66K
(3200.00%↑ Y/Y)
Purchases of property and
equipment
$13K
(-90.71%↓ Y/Y)
Payment of deferred
offering costs
$144K
Net cash used in
operating activities
-$19,463K
(28.58%↑ Y/Y)
Canceled cashflow
$8,602K
Net loss
-$24,837K
Gain on sale of assets
$1,770K
Prepaid expenses and
other current assets
$1,013K
(-10.67%↓ Y/Y)
Other assets
$339K
(534.62%↑ Y/Y)
Operating lease liability
-$106K
(-857.14%↓ Y/Y)
Back
Back
Cash Flow
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)
source: myfinsight.com